Earle Burgess: Results from the ENZADA trial for men with advanced prostate cancer
Earle Burgess, Chief of Genitourinary Oncology Section at Atrium Health Levine Cancer Institute, shared an article he and his colleagues authored on LinkedIn:
“Want new information for men with metastatic prostate cancer?
Our results from the ENZADA trial for men with advanced prostate cancer are now published!
We studied the treatment combination of enzalutamide (Xtandi) with androgen deprivation therapy (ADT) and chemotherapy (docetaxel) in men with newly diagnosed metastatic prostate cancer.
We discovered that adding enzalutamide led to a higher rate of undetectable PSA blood levels after a year of treatment compared to a prior study using ADT and chemotherapy only.
Most importantly, we also found that men whose PSA was undetectable after a year of treatment lived longer than those whose PSA was still detectable.
Thank you to all the patients, staff and Astellas/Pfizer who made this clinical trial possible!
Read the full publication here.”
Authors: Earle F. Burgess et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023